Edition:
United States

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

33.72EUR
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
€33.72
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
68,865
52-wk High
€56.48
52-wk Low
€17.24

Select another date:

Fri, Nov 17 2017

BRIEF-Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance

* CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celyad reports first complete response in relapsed refractory AML patient in THINK trial ‍​

* REPORTS A FIRST COMPLETE RESPONSE IN A RELAPSED REFRACTORY AML PATIENT IN THE THINK TRIAL ‍​

BRIEF-Celyad SA files for mixed shelf offering of up to $250 mln

* Celyad SA files for mixed shelf offering of up to $250 million - SEC filing ‍​ Source text: [http://bit.ly/2xBg9Sn] Further company coverage:

BRIEF-Celyad H1 operating loss narrows to 13.7 million euros

* H1 OPERATING LOSS EUR 13.7 MILLION VERSUS LOSS OF EUR 17.2 MILLION YEAR AGO

BRIEF-BioLife Solutions executes supply agreement with Celyad for CryoStor

* Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers

BRIEF-Celyad publishes additional pre-clinical data in support of THINK trial ‍​

* PUBLISHES ADDITIONAL PRE-CLINICAL DATA IN SUPPORT OF THINK TRIAL ‍​

Select another date: